ChemicalBook > Product Catalog >Pharmaceutical intermediates >Bulk Drug Intermediates >(aR,3aS,4S,6S,7aR)-Hexahydro-3a,8,8-trimethyl-alpha-(2-methylpropyl)-4,6-methano-1,3,2-benzodioxaborole-2-methanamine 2,2,2-trifluoroacetate

(aR,3aS,4S,6S,7aR)-Hexahydro-3a,8,8-trimethyl-alpha-(2-methylpropyl)-4,6-methano-1,3,2-benzodioxaborole-2-methanamine 2,2,2-trifluoroacetate

(aR,3aS,4S,6S,7aR)-Hexahydro-3a,8,8-trimethyl-alpha-(2-methylpropyl)-4,6-methano-1,3,2-benzodioxaborole-2-methanamine 2,2,2-trifluoroacetate Structure
CAS No.
179324-87-9
Chemical Name:
(aR,3aS,4S,6S,7aR)-Hexahydro-3a,8,8-trimethyl-alpha-(2-methylpropyl)-4,6-methano-1,3,2-benzodioxaborole-2-methanamine 2,2,2-trifluoroacetate
Synonyms
(1R)-(S)-PINANEDIOL 1-AMMONIUM TRIFLUOROACETATE-3-METHYLBUTANE-1-BORONATE;(R)-3-Methyl-1-((3aS,4S,6S,7aR)-3a,5,5-triMethylhexahydro-4,6-Methanobenzo[d][1,3,2]dioxaborol-2-yl)butan-1-aMine 2,2,2-trifluoroacetate;2,6<SUP>/SUP>(R)-BoroL;6-methano-1;Bortezomib INT A;eu-(+)-PinanedioL;7aR)-Hexahydro-3a
CBNumber:
CB21511721
Molecular Formula:
C17H29BF3NO4
Molecular Weight:
379.23
MOL File:
179324-87-9.mol
Modify Date:
2024/4/3 15:02:28

(aR,3aS,4S,6S,7aR)-Hexahydro-3a,8,8-trimethyl-alpha-(2-methylpropyl)-4,6-methano-1,3,2-benzodioxaborole-2-methanamine 2,2,2-trifluoroacetate Properties

Melting point 157-159°C
storage temp. under inert gas (nitrogen or Argon) at 2-8°C
solubility Ethanol (Slightly), Methanol (Slightly)
form Solid
color White to Off-White
InChI InChI=1/C15H28BNO2.C2HF3O2/c1-9(2)6-13(17)16-18-12-8-10-7-11(14(10,3)4)15(12,5)19-16;3-2(4,5)1(6)7/h9-13H,6-8,17H2,1-5H3;(H,6,7)/t10-,11-,12+,13-,15-;/s3
InChIKey SRFQKJZNJYTMNI-XXOUUVOINA-N
SMILES C(F)(F)(F)C(=O)O.C[C@@]12OB([C@@H](N)CC(C)C)O[C@]1([H])C[C@]1([H])C[C@@]2([H])C1(C)C |&1:8,11,18,21,24,r|
CAS DataBase Reference 179324-87-9(CAS DataBase Reference)

SAFETY

Risk and Safety Statements

Symbol(GHS) 
GHS07
Signal word  Warning
Hazard statements  H302-H315-H319-H332-H335
Precautionary statements  P261-P280-P305+P351+P338
Risk Statements  36/37/38
Safety Statements  26-36/37/39
HS Code  29209090

(aR,3aS,4S,6S,7aR)-Hexahydro-3a,8,8-trimethyl-alpha-(2-methylpropyl)-4,6-methano-1,3,2-benzodioxaborole-2-methanamine 2,2,2-trifluoroacetate price More Price(1)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Sigma-Aldrich(India) BCH00043 (R)-Boroleucine (1S,2S,3R,5S)-(+)-2,3-pinanediol ester trifluoroacetate 179324-87-9 1G ₹71737.28 2022-06-14 Buy
Product number Packaging Price Buy
BCH00043 1G ₹71737.28 Buy

(aR,3aS,4S,6S,7aR)-Hexahydro-3a,8,8-trimethyl-alpha-(2-methylpropyl)-4,6-methano-1,3,2-benzodioxaborole-2-methanamine 2,2,2-trifluoroacetate Chemical Properties,Uses,Production

Chemical Properties

White Solid

Uses

Bortezomib (B675700) intermediate. A boronic acid dipeptide derivative as proteasome inhibitors.

(aR,3aS,4S,6S,7aR)-Hexahydro-3a,8,8-trimethyl-alpha-(2-methylpropyl)-4,6-methano-1,3,2-benzodioxaborole-2-methanamine 2,2,2-trifluoroacetate Preparation Products And Raw materials

Raw materials

Preparation Products

Global( 344)Suppliers
Supplier Tel Country ProdList Advantage Inquiry
OPULENT PHARMA +91-9106692785 +91-9106692785 Gujarat, India 479 58 Inquiry
Molkem Chemicals +91-917228022464 +91-7228022464 Ahmedabad, India 138 58 Inquiry
RANI LIFE SCIENCES PVT LTD +91-8008797507 +91-8008797507 Hyderabad, India 37 58 Inquiry
VGS SYNTHESIS PRIVATE LIMITED +91-9866975588 +91-9866975588 Hyderabad, India 1817 58 Inquiry
RS LIFE SCIENCES +91-9963585741 +91-9963585741 Hyderabad, India 32 58 Inquiry
Rivashaa Agrotech Biopharma Pvt. Ltd. +91-26463395 +91-7926462688 Gujarat, India 1615 58 Inquiry
Myosynth Laboratories Pvt Ltd +91-8913266227 +91-9885891884 AndhraPradesh, India 49 58 Inquiry
Vepan Pharmatech Pvt Ltd +91-9908788828 +91-9966094448 Telangana, India 391 58 Inquiry
VIVAN Life Sciences Pvt. Limited. +91(22) 2544 4584 / 2544 4585 New Delhi, India 138 50 Inquiry
Manus Aktteva +91 (79) 6512-3395 New Delhi, India 581 34 Inquiry
(R)-BoroLeu-(+)-Pinanediol-CF3COOH (R)-BoroLeu-(+)-Pinanediol-CF3CO2H (aR,3aS,4S,6S,7aR)-Hexahydro-3a,8,8-trimethyl-alpha-(2-methylpropyl)-4,6-methano-1,3,2-benzodioxaborole-2-methanamine 2,2,2-trifluoroacetate (αR)-(1S,2S,3R,5S)-Pinanediol-1-amino-3-methylbutane-1-boronate Trifluoroacetate Bortezomib Intermediate 1 (R)-BoroLeu-(+)-Pinanediol trifluoroacetate (αR,3aS,4S,6S,7aR)- (alphaR,3as,4s,6s,7ar)-Hexahydro-3a,8,8-triMethyl-alpha-(2-Methylpropyl)-4,6-Methano-1,3,2-benzodioxaborole-2-MethanaMine 2,2,2-trifluoroacetate Pinanedioltrifluoroacetate salt- BortezoMib I(aR,3aS,4S,6S,7aR)-Hexahydro-3a,8,8-triMethyl-alpha-(2-Methylpropyl)-4,6-Methano-1,3,2-benzodioxaborole-2-MethanaMine 2,2,2-trifluoroacetate (R)-3-Methyl-1-((3aS,4S,6S,7aR)-3a,5,5-triMethylhexahydro-4,6-Methanobenzo[d][1,3,2]dioxaborol-2-yl)butan-1-aMiniuM 2,2,2-trifluoroacetate (αR)-(1S,2S,3R,5S)-Pinanediol-1-aMino-3-Methylbutane-1-boronate Trifluoroacetic Acid Salt (R)-Boroleucine-(1S,2S,3R,5S)-(+)-pinanediol ester trifluoroacetate Bortezomib Intermediates Ixazomib intermediate (aR,3aS,4S,6S,7aR)-Hexahydro-3a,8,8-trimethyl-alpha-(2-methylpropyl)-4,6-methano-1,3,2-benzodioxaborole-2-methamine 2,2,2-trifluoroacetate Bortezomib INT A (R)-BoroLeu-(+)-Pinanediol-CF3COOH N-4 (1R)-(S)-pinanediol 1-aMMoniuM trifiuoroacetate-3-Methylbutane-1-boronate (R)-Boroleucine-(1S,2S,3R,5S)-(+)-pinanediol ester trifluoroacetate 98% (aR,3aS,4S,6S,7aR)-Hexahydro-3a,8,8-trimethyl-α-(2-methylpropyl)-4,6-methano-1,3,2-benzodioxaborole-2-methanamine 2,2,2-trifluoroacetate (R)-3-Methyl-1-[(3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methano-1,3,2-benzodioxaborol-2-yl]-1-butanamine 2,2,2-Trifluoroacetate BoroLeu-(+)-Pinanediol (1R)-3-methyl-1-[(1S,2S,6R,8S)-2,9,9-trimethyl-3,5-dioxa-4-boratricyclo[6.1.1.0< /SUP> ]decan-4-yl]butan-1-amine 2,6< SUP> (aR,3aS,4S,6S,7aR)-Hexahydro-3a,8,8-trimethyl-α-(2-methylpropyl)-4,6-methano-1,3,2-benzodioxaborole- (R)-BoroL eu-(+)-PinanedioL (1S,2S,3R,5S)-Pinane-2,3-diol leucineboronate trifluoroacetate salt (aR,3aS,4S,6S,7aR)-Hexahydro-3a,8,8-trimethyl-alpha-(2-methylpropyl)-4,6-methano-1,3,2-benzodioxabor Bortezomib Intermediate A 4,6-Methano-1,3,2-benzodioxaborole-2-methanamine, hexahydro-3a,8,8-trimethyl-α-(2-methylpropyl)-, (αR,3aS,4S,6S,7aR)-, 2,2,2-trifluoroacetate (1:1) Ixazomib Impurity 28 2-benzodioxaborole-2-methanamine 2 6-methano-1 7aR)-Hexahydro-3a 8-trimethyl-alpha-(2-methylpropyl)-4 (R)-BoroLeu-(+)-Pinanediol trifluoroacetate (Bortezomib Impurity) Bortezomib Amino R Isomer (aR,3aS,4S,6S,7aR)-Hexahydro-3a,8,8-trimethyl-alpha-(2-methy... (1R)-(S)-Pinanediol 1-ammonium trifluoroacetate-3-methylbutane-1-boronate (TFA) (αR)-(1S,2S,3R,5S)-Pinanediol-1-amino-3-methylbutane-1-boronate Trifluoroacetate (1R)-(S)-pinanediol-1-Ammonium Trifluoroacetate-3-methlbutane-1-boronate (αR)-(1S,2S,3R,5S)-Pinanediol-1-amino-3-methylbutane-1-boronate Trifluoroacetic Acid Salt (1R)-(S)-PINANEDIOL 1-AMMONIUM TRIFLUOROACETATE-3-METHYLBUTANE-1-BORONATE (R)-3-Methyl-1-((3aS,4S,6S,7aR)-3a,5,5-triMethylhexahydro-4,6-Methanobenzo[d][1,3,2]dioxaborol-2-yl)butan-1-aMine 2,2,2-trifluoroacetate (R) Pinanediol 1-amino-3-methylbutyl borate trifluoroacetate 4,6-Methano-1,3,2-benzodioxaborole-2-methanamine, hexahydro-3a,8,8-trimethyl-α-(2-methylpropyl)-, (αR,3aS,4S,6S,7aR)-,2,2,2-trifluoroacetate (1:1) (aR,3aS,4S,6S,7aR)- hexahydro -3a,8,8- trimethyl -alpha-(2- methylpropyl) -4,6- methyl bridge -1,3,2- benzodioxolane -2- methylamine 2,2,2- trifluoroacetate (αR,3aS,4S,6S,7aR)-hexahydro-3a,8,8-trimethyl-α-(2-methylpropyl)-4,6-Methano-1,3,2-benzodioxaborole-2-methanamine 2,2,2-trifluoroacetate (1:1) (aR,3aS,4S,6S,7aR)-Hexahydro-3a,5,5-trimethyl-a-(2-methylpropyl)-4,6-methano-1,3,2-benzodioxaborole-2-methanamine TFA (R)-Boroleucine (1S 2S 3R 5S)-(+)-2 3-pinanediol ester trifluoroacetate. (R)-1-Amino-3-methylbutylboronic acid pinanediol ester trifluoroacetate (R)-BoroLeu-(+)-Pinanedioltrifluoroacetate salt (aR,3aS,4S,6S,7aR)-Hexahydro-3a,8,8-trimethyl-alpha-(2-methylpropyl)-4,6-methano-1,3,2-benzodiox